🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Doxycycline Sandoz 100 mg tabletten, Doxycycline EG 200 mg Tabletten

    The George Institute

    Sexually Transmitted Infections

    phase 3 small molecule active

    1 trial

  2. Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment

    United Therapeutics Europe Ltd

    COVID19

    phase 3 small molecule active

    1 trial

  3. Drug: Ivonescimab Injection

    Summit Therapeutics

    Metastatic Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  4. Durvalumab + SoC chemotherapy

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  5. EB-101

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa

    phase 3 mab completed

    1 trial

  6. EB-101 Surgical application of RDEB wounds

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa

    phase 3 mab active

    1 trial

  7. EFGARTIGIMOD ALFA, JNJ-80202135

    Janssen-Cilag International N.V.

    generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  8. EIK1001

    Eikon Therapeutics

    Non Small Cell Lung Cancer (Squamous or Non Squamous)

    phase 3 small molecule active

    1 trial

  9. EIK1001

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  10. ELECTROLYTES , VIALEBEX 200 g/L, solution pour perfusion

    Pari Pharma GmbH

    Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

    phase 3 small molecule active

    1 trial

  11. ELOXATINE 5 mg/ml, solution à diluer pour perfusion, ELOXATINE 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer and rectal with liver metastasis

    phase 3 small molecule active

    1 trial

  12. EMB-Fatol® 100 mg, Tabletten, The placebo for Amikacin Liposome for Inhalation Suspension drug product is a white translucent suspension consisting of dipalmitoylphosphatidylcholine (DPPC) and cholesterol, which are dispersed in 1.5% (w/w) sodium chloride solution. The placebo is filled into the same container closure system of the drug product, Azithromycin-ratiopharm 250mg Filmtabletten, Azithromycin STADA® 250 mg Filmtabletten, Azithromycin AL 250 mg Filmtabletten, Azitromicina Teva 250 mg comprimidos re

    Insmed Limited

    "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"

    phase 3 small molecule active

    1 trial

  13. ENTECAVIR , VAY736, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled pen, TENOFOVIR ALAFENAMIDE , -, VAY736, TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  14. ERIBULIN MESYLATE, VINORELBINE, GEMCITABINE, CAPECITABINE, CAPECITABINE, Datopotamab deruxtecan

    AstraZeneca AB

    "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"

    phase 3 small molecule active

    1 trial

  15. ETC-1002

    Esperion Therapeutics

    Hypercholesterolemia

    phase 3 small molecule completed

    6 trials

  16. ETEPLIRSEN (AVI-4658)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  17. Educational Dementia training

    United Therapeutics Europe Ltd

    Dementia

    phase 3 other active

    1 trial

  18. Educational Intervention

    United Therapeutics Europe Ltd

    Hematologic Malignancies

    phase 3 other active

    1 trial

  19. Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)

    United Therapeutics Europe Ltd

    Cardiovascular Disease

    phase 3 mab completed

    1 trial

  20. Elaprase 2 mg/ml concentrate for solution for infusion

    Denali Therapeutics

    Mucopolysaccharidosis Type II [MPS II]

    phase 3 small molecule active

    1 trial

  21. Elenestinib

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis

    phase 3 small molecule active

    1 trial

  22. Eliquis 5 mg film-coated tablets, ACETYLSALICYLIC ACID

    Pari Pharma GmbH

    Aortic bioprothesis implanted patient for valvular heart disease

    phase 3 small molecule active

    1 trial

  23. Eltrombopag 25 MG Oral Tablet

    The First People's Hospital of Lianyungang

    Stem Cell Transplant Complications

    phase 3 small molecule completed

    1 trial

  24. Empagliflozin 10 mg

    United Therapeutics Europe Ltd

    Acute Myocardial Infarction

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources